Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 35

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant

Hansen, Henrik H., Hansen, Gitte, Tang-Christensen, Mads, Larsen, Philip J., Axel, Anne Marie D., Raben, Anne, Mikkelsen, Jens D.·2010·European Journal of Pharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejphar.2010.03.026

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 30

  1. Astrup, 2008, Effect of tesofensine on body weight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1906, 10.1016/S0140-6736(08)61525-1 · DOI · Paper page
  2. Astrup, 2008, Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease, Obesity (Silver Spring Md), 16, 1363, 10.1038/oby.2008.56 · DOI
  3. Balcioglu, 2000, Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid, Neuropharmacology, 39, 2352, 10.1016/S0028-3908(00)00083-6 · DOI
  4. Billes, 2007, Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice, Neuropsychopharmacology, 32, 822, 10.1038/sj.npp.1301155 · DOI
  5. Billes, 2008, Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis, Neuropsychopharmacology, 33, 1287, 10.1038/sj.npp.1301526 · DOI
  6. Brown, 2001, Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y, Br. J. Pharmacol., 132, 1898, 10.1038/sj.bjp.0704030 · DOI
  7. Bush, 2006, Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice, Endocrine, 29, 375, 10.1385/ENDO:29:2:375 · DOI
  8. Connoley, 1999, Thermogenic effects of sibutramine and its metabolites, Br. J. Pharmacol., 126, 1487, 10.1038/sj.bjp.0702446 · DOI
  9. Fernstrom, 2008, The development of tolerance to drugs that suppress food intake, Pharmacol. Ther., 117, 105, 10.1016/j.pharmthera.2007.09.001 · DOI
  10. Fisas, 2006, Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats, Br. J. Pharmacol., 148, 973, 10.1038/sj.bjp.0706807 · DOI
  11. Fulton, 2006, Leptin regulation of the mesoaccumbens dopamine pathway, Neuron, 51, 811, 10.1016/j.neuron.2006.09.006 · DOI · Paper page
  12. Gary-Bobo, 2007, Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, 46, 122, 10.1002/hep.21641 · DOI · Paper page
  13. Glick, 2000, Enantioselective behavioral effects of sibutramine metabolites, Eur. J. Pharmacol., 397, 93, 10.1016/S0014-2999(00)00216-8 · DOI
  14. Goldstein, 1992, Beneficial health effects of modest weight loss, Int. J. Obes. Relat. Metab. Disord., 16, 397
  15. Golozoubova, 2006, Locomotion is the major determinant of sibutramine-induced increase in energy expenditure, Pharmacol. Biochem. Behav., 83, 517, 10.1016/j.pbb.2006.03.014 · DOI
  16. Haslam, 2005, Obesity, Lancet, 366, 1197, 10.1016/S0140-6736(05)67483-1 · DOI · Paper page
  17. Heal, 1998, A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents, Br. J. Pharmacol., 125, 301, 10.1038/sj.bjp.0702067 · DOI
  18. Jackson, 1997, Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat, Br. J. Pharmacol., 121, 1613, 10.1038/sj.bjp.0701311 · DOI
  19. Jackson, 1997, Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat, Br. J. Pharmacol., 121, 1758, 10.1038/sj.bjp.0701312 · DOI
  20. Kahn, 2000, Obesity and insulin resistance, J. Clin. Invest., 106, 473, 10.1172/JCI10842 · DOI · Paper page
  21. Lehr, 2008, Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic–pharmacodynamic modelling approach, Br. J. Pharmacol., 153, 164, 10.1038/sj.bjp.0707539 · DOI
  22. Levin, 2000, Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats, Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R2222, 10.1152/ajpregu.2000.279.6.R2222 · DOI
  23. Meguid, 2000, Hypothalamic dopamine and serotonin in the regulation of food intake, Nutrition (Burbank, Los Angeles County, Calif), 16, 843, 10.1016/S0899-9007(00)00449-4 · DOI · Paper page
  24. Nogueiras, 2008, Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats, Diabetes, 57, 2977, 10.2337/db08-0161 · DOI · Paper page
  25. Palmiter, 2007, Is dopamine a physiologically relevant mediator of feeding behavior?, Trends Neurosci., 30, 375, 10.1016/j.tins.2007.06.004 · DOI · Paper page
  26. Paulsen, 2010, Characterization of beta-Cell Mass and Insulin Resistance in Diet-induced Obese and Diet-resistant Rats, Obesity (Silver Spring, Md.), 18, 266, 10.1038/oby.2009.245 · DOI
  27. Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761 · DOI · Paper page
  28. Tizzano, 2008, The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity, J. Pharmacol. Exp. Ther., 324, 1111, 10.1124/jpet.107.133132 · DOI
  29. Volkow, 2005, How can drug addiction help us understand obesity?, Nat. Neurosci., 8, 555, 10.1038/nn1452 · DOI · Paper page
  30. Wortley, 1999, Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors, Br. J. Pharmacol., 128, 659, 10.1038/sj.bjp.0702859 · DOI

Cited by

See all 35

Metadata

Authors
Hansen, H. H., Hansen, G., Tang-Christensen, M., Larsen, P. J., Axel, A. M. D., Raben, A., & Mikkelsen, J. D.
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
2010-06
Volume
636
Issue
1-3
Pages
88-95
ISSN
0014-2999
Cited by
35
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. https://app.cochat.ai/papers/10.1016/j.ejphar.2010.03.026
The paper
Hansen, H. H., Hansen, G., Tang-Christensen, M., Larsen, P. J., Axel, A. M. D., Raben, A., & Mikkelsen, J. D. (2010). The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2010.03.026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.